| Name | Title | Contact Details |
|---|
Linkwell Health is a Needham Heights, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cirrus Health is an organization uniquely qualified to successfully adapt to the ever-changing healthcare environment. While the complexity of today's healthcare creates barriers for some companies, it is a market of opportunities for Cirrus Health.
The New York Foundling Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The New York Foundling Hospital is based in New York, NY. You can find more information on The New York Foundling Hospital at www.nyfoundling.org
Southern Heritage Bank is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Louisville, KY. To find more information about Southern Heritage Bank, please visit www.southernheritagebank.com
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.